Hwang Y S, Hsieh T J, Lee Y J, Tsai J H
Department of Internal Medicine, Kaoshiung Medical College, Republic of China, Taiwan.
Am J Hypertens. 1998 Nov;11(11 Pt 1):1344-51. doi: 10.1016/s0895-7061(98)00170-8.
Endothelin-1 (ET-1) is a potent vasoconstrictive peptide with diverse physiologic actions and has been considered to be involved in the pathogenesis of hypertension. We sought to investigate the role of renal synthesis of ET-1 in the regulation of daily sodium homeostasis and the possible contribution of renal synthesized ET-1 in the pathogenesis of essential hypertension (EHT). Urinary ET-1-like immunoreactivity (ET-1-L1) was measured by a radioimmunoassay after extraction in 23 EHT patients without detectable target organ damage, and in 11 normotensive controls. All study subjects received a controlled diet during an 8-day study period. Urinary and blood samples were collected by four sampling periods/day from the 4th to 6th days, and on the 7th day, study subjects were given an intravenous infusion of 1250 mL normal saline over 2 h. In the basal state, the urinary sodium and ET-1-L1 excretions showed diurnal patterns in both the normal and hypertensive groups, and urinary ET-1-L1 excretion rate correlated well with urinary sodium excretion rate. There were no differences found in plasma ET-1 levels, urinary ET-1-L1, and sodium excretion rates between the control and hypertensive groups. After saline infusion, ten hypertensive patients showed nonexaggerated natriuresis, and the 24-h urinary ET-1-L1 excretion (47.0+/-4.0 pmol/day), collected during the day of saline infusion, was significantly lower than that of the control group (86.3+/-10.0 pmol/day) or the exaggeratedly natriuretic hypertensive patients (91.7+/-8.4 pmol/ day). Our results suggest that renal ET-1 may be responsible for the renal handling of sodium homeostasis, and alteration of renal ET-1 synthesis may be a contributory factor in the pathogenesis of essential hypertension and salt sensitivity.
内皮素-1(ET-1)是一种具有多种生理作用的强效血管收缩肽,被认为与高血压的发病机制有关。我们试图研究肾脏合成ET-1在日常钠稳态调节中的作用,以及肾脏合成的ET-1在原发性高血压(EHT)发病机制中的可能作用。采用放射免疫分析法,对23例无明显靶器官损害的EHT患者和11例血压正常的对照者进行尿液提取后测定尿ET-1样免疫反应性(ET-1-L1)。所有研究对象在为期8天的研究期间接受控制饮食。在第4至6天,每天分4个采样时段收集尿液和血液样本,在第7天,研究对象在2小时内静脉输注1250 mL生理盐水。在基础状态下,正常组和高血压组的尿钠和ET-1-L1排泄均呈现昼夜节律,尿ET-1-L1排泄率与尿钠排泄率密切相关。对照组和高血压组之间的血浆ET-1水平、尿ET-1-L1和钠排泄率无差异。输注生理盐水后,10例高血压患者出现利钠反应不明显,在输注生理盐水当天收集的24小时尿ET-1-L1排泄量(47.0±4.0 pmol/天)明显低于对照组(86.3±10.0 pmol/天)或利钠反应明显的高血压患者(91.7±8.4 pmol/天)。我们的结果表明,肾脏ET-1可能负责肾脏对钠稳态的处理,肾脏ET-1合成的改变可能是原发性高血压发病机制和盐敏感性的一个促成因素。